Stathmin1 Plays Oncogenic Role and is a Target of MicroRNA-223 in Gastric Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Apr 4

PMID 22470493

Citations 52

Authors

Wei Kang

Joanna H M Tong

Anthony W H Chan

Raymond W M Lung

Shuk Ling Chau

Queenie W L Wong

Nathalie Wong

Jun Yu

Alfred S L Cheng

Ka Fai To

Affiliations

Soon will be listed here.

Abstract

Stathmin1 (STMN1) is a candidate oncoprotein and prognosis marker in several kinds of cancers. This study was aimed to analyze its expression and biological functions in gastric cancer. The expression of STMN1 was evaluated by qRT-PCR, western blot and immunohistochemistry. The biological function of STMN1 was determined by MTT proliferation assays, monolayer colony formation and cell invasion assays using small interference RNA technique in gastric cancer cell lines. We also explored the regulation of STMN1 expression by microRNA-223. STMN1 was upregulated in gastric cancer cell lines and primary gastric adenocarcinomas. STMN1-positive tumors were more likely to be found in old age group and associated with p53 nuclear expression. In diffuse type gastric adenocarcinomas, STMN1 expression was correlated with age (p = 0.043), T stage (p = 0.004) and lymph node metastasis (p = 0.046). Expression of STMN1 in diffuse type gastric adenocarcinoma was associated with poor disease specific survival by univariate analysis (p = 0.01). STMN1 knockdown in AGS and MKN7 cell lines suppressed proliferation (p<0.001), reduced monolayer colony formation (p<0.001), inhibited cell invasion and migration ability (p<0.001) and induced G1 phase arrest. siSTMN1 could also suppress cell growth in vivo (p<0. 01). We finally confirmed that STMN1 is a putative downstream target of miR-223 in gastric cancer. Our findings supported an oncogenic role of STMN1 in gastric cancer. STMN1 might serve as a prognostic marker and a potential therapeutic target for gastric cancer.

Citing Articles

Tumor Microenvironment Remodeling in Gastrointestinal Cancer: Role of miRNAs as Biomarkers of Tumor Invasion.

Lucarini V, Nardozi D, Angiolini V, Benvenuto M, Focaccetti C, Carrano R Biomedicines. 2023; 11(6).

PMID: 37371856 PMC: 10296425. DOI: 10.3390/biomedicines11061761.

Molecular Biomarkers of Malignant Transformation in Head and Neck Dysplasia.

Ranganath K, Feng A, Franco R, Varvares M, Faquin W, Naunheim M Cancers (Basel). 2022; 14(22).

PMID: 36428690 PMC: 9688631. DOI: 10.3390/cancers14225581.

Exosomal CXCL14 Contributes to M2 Macrophage Polarization through NF-B Signaling in Prostate Cancer.

Tian H, Liang Q, Shi Z, Zhao H Oxid Med Cell Longev. 2022; 2022:7616696.

PMID: 35669852 PMC: 9166984. DOI: 10.1155/2022/7616696.

Immunohistochemical expression of stathmin in oral dysplasia: An original study with an insight of its action on microtubules.

Vadla P, Deepthi G, Kumar C, Bashamalla R, Syeda N, Naramala S J Oral Maxillofac Pathol. 2021; 25(2):247-252.

PMID: 34703117 PMC: 8491364. DOI: 10.4103/0973-029X.325122.

Recent Advances in Surface-Enhanced Raman Scattering Magnetic Plasmonic Particles for Bioapplications.

Huynh K, Hahm E, Noh M, Lee J, Pham X, Lee S Nanomaterials (Basel). 2021; 11(5).

PMID: 34064407 PMC: 8147842. DOI: 10.3390/nano11051215.

References

Yuan R, Jeng Y, Chen H, Lai P, Pan H, Hsieh F . Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006; 209(4):549-58. DOI: 10.1002/path.2011. View

Johnsen J, Aurelio O, Kwaja Z, Jorgensen G, Pellegata N, Plattner R . p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer. 2000; 88(5):685-91. DOI: 10.1002/1097-0215(20001201)88:5<685::aid-ijc1>3.0.co;2-z. View

Ahn J, Murphy M, Kratowicz S, Wang A, Levine A, GEORGE D . Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene. 1999; 18(43):5954-8. DOI: 10.1038/sj.onc.1202986. View

Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y . An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell. 2007; 129(3):617-31. DOI: 10.1016/j.cell.2007.02.048. View

Farazi T, Spitzer J, Morozov P, Tuschl T . miRNAs in human cancer. J Pathol. 2010; 223(2):102-15. PMC: 3069496. DOI: 10.1002/path.2806. View

Wang J, Yu M, Yu G, Bian J, Deng X, Wan X . Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun. 2010; 394(1):184-8. DOI: 10.1016/j.bbrc.2010.02.145. View

Leung W, Wu K, Wong C, Cheng A, Ching A, Chan A . Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis. 2008; 29(8):1648-54. DOI: 10.1093/carcin/bgn156. View

Sun W, Shen W, Yang S, Hu F, Li H, Zhu T . miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-β. Cell Res. 2010; 20(10):1158-69. DOI: 10.1038/cr.2010.134. View

Brenner H, Rothenbacher D, Arndt V . Epidemiology of stomach cancer. Methods Mol Biol. 2008; 472:467-77. DOI: 10.1007/978-1-60327-492-0_23. View

10.

Johnnidis J, Harris M, Wheeler R, Stehling-Sun S, Lam M, Kirak O . Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008; 451(7182):1125-9. DOI: 10.1038/nature06607. View

11.

Zhang Y, Guo J, Li D, Xiao B, Miao Y, Jiang Z . Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol. 2009; 27(3):685-9. DOI: 10.1007/s12032-009-9269-x. View

12.

Wong Q, Lung R, Law P, Lai P, Chan K, To K . MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 2008; 135(1):257-69. DOI: 10.1053/j.gastro.2008.04.003. View

13.

Gan L, Guo K, Li Y, Kang X, Sun L, Shu H . Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncol Rep. 2010; 23(4):1037-43. DOI: 10.3892/or_00000730. View

14.

Zheng P, Liu Y, Chen L, Liu X, Xiao Z, Zhao L . Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res. 2010; 9(10):4897-905. DOI: 10.1021/pr100712t. View

15.

Chan A, Chan M, Lee T, Ng E, Leung W, Lau J . Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep. 2005; 13(5):937-41. View

16.

Sugatani T, Hruska K . MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem. 2007; 101(4):996-9. DOI: 10.1002/jcb.21335. View

17.

Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L . Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate. 2007; 67(10):1038-52. DOI: 10.1002/pros.20601. View

18.

Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M . Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res. 2009; 69(6):2234-43. DOI: 10.1158/0008-5472.CAN-08-3338. View

19.

Hsieh S, Huang S, Yu M, Yeh T, Chen T, Lin Y . Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog. 2010; 49(5):476-87. DOI: 10.1002/mc.20627. View

20.

Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks M, Shih I . Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011; 24(9):1248-53. DOI: 10.1038/modpathol.2011.85. View